February 27, 2020 | Vensana in the News

Vensana—Is Medtech Investing on the Rebound?

22

Novel FDA PMA & de novo 510k approvals

61

U.S. Commercial Product Launches

40

Level I Clinical Trials

34

Strategic Financings

32

Exits by IPO or M&A